Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
SRPT News
Sarepta Therapeutics Inc. ( (SRPT) ) has released its Q3 earnings. Here is a breakdown of the information Sarepta Therapeutics Inc. presented to its investors....
Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed disappointing drug-trial data, which could leng...
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are plunging in extended trading Monday after the company reported third-quarter results and provided an update on...
Analyst ratings
58%
of 26 ratingsMore SRPT News
Sarepta stock crashed late Monday after the biotech company said two of its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys 53, failed their confirmat...
Reports Q3 revenue $399.36M, consensus $337.03M. “We are pleased to have met our primary post-marketing obligation with the completion of ESSENCE, a particularl...
In recent trading, shares of Sarepta Therapeutics Inc (Symbol: SRPT) have crossed above the average analyst 12-month target price of $23.41, changing hands for...
Sarepta Therapeutics recently confirmed it will announce its third quarter 2025 financial results and provided updates regarding shifts in institutional investo...
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel , our Y...
Piper Sandler analyst Biren Amin raised the firm’s price target on Sarepta (SRPT) to $16 from $15 and keeps a Neutral rating on the shares. The firm says its la...